Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue GlobeNewswire January 13, 2026 Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer […]

Voting Rights and Shares Capital of the Company GlobeNewswire January 13, 2026 In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorite des Marches Financiers) PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE) — Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code:

Solitron Devices, Inc. Announces Fiscal 2026 Third Quarter Results GlobeNewswire January 13, 2026 WEST PALM BEACH, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) — Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2026 third quarter results. FISCAL 2026 THIRD QUARTER HIGHLIGHTS – Net sales increased 49% to approximately $5.02

(NasdaqGM:NUAI), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether New Era and certain of

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of New Era Energy & Digital, Inc. – NUAI GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI).

(NASDAQ:RARE), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have

(NASDAQ:MREO), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc – MREO GlobeNewswire January 13, 2026 NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to

(NasdaqGM:BGIN), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Bgin Blockchain Limited (“Bgin” or the “Company”) (NASDAQ: BGIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bgin and certain of its officers and/or directors have engaged in securities